التفاصيل البيبلوغرافية
| العنوان: |
Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma. |
| المؤلفون: |
Mignard, Claire, Deschamps Huvier, Aurélie, Gillibert, André, Duval Modeste, Anne Bénédicte, Dutriaux, Caroline, Khammari, Amir, Avril, Marie-Françoise, Kramkimel, Nora, Mortier, Laurent, Marcant, Pierre, Lesimple, Thierry, Gaudy-Marqueste, Caroline, Lesage, Candice, Machet, Laurent, Aubin, François, Meyer, Nicolas, Beneton, Nathalie, Jeudy, Géraldine, Montaudié, Henri, Arnault, Jean-Philippe |
| المصدر: |
Journal of Oncology; 12/2/2018, p1-9, 9p |
| مصطلحات موضوعية: |
MELANOMA immunotherapy, UVEAL diseases, THERAPEUTIC use of monoclonal antibodies, DERMATOLOGY, CANCER chemotherapy, TREATMENT effectiveness |
| مستخلص: |
Background. The objective was to assess the response rate and survival of patients with metastatic mucosal melanoma (MM) and uveal melanoma (UM) treated with anti-CTLA-4 or anti-PD-1 monoclonal antibodies (mAbs). Methods. A multicenter retrospective study was performed in 25 dermatology departments in France. All patients with stage III-C to IV MM or UM who were treated with anti-CTLA-4 or anti-PD-1 mAbs between 2008 and 2016 were included and compared after adjustment for main prognostic factors with a second cohort of patients treated with chemotherapy. Tumor response was evaluated according to RECIST v. 1.1 criteria at Week 12. Results. Four-hundred-and-thirty-nine patients were included, 229 MM (151 immunotherapy, 78 chemotherapy) and 210 UM (100 immunotherapy, 110 chemotherapy). Response rates of MM patients treated with immunotherapy were 18/151 (11.9%; 95% CI:7.2%-18.2%), versus 11/78 (14.1%, 95% CI:7.3%-23.8%) in patients treated with chemotherapy (p=0.87). No tumor response was observed in UM patients treated with immunotherapy, versus 4/110 responses (3.6%, 95% CI:1.0-9.0%) in patients treated with chemotherapy (p=0.15). The adjusted overall survival (OS) of MM patients treated with immunotherapy was longer than that of patients treated with chemotherapy HR=0.62 (95% CI: 0.43-0.91), p=0.014, with an unadjusted median OS of 15.97 months [interquartile range (IQR)=6.89-27.11] and 8.82 months [IQR=5.02-14.92], respectively. The adjusted OS of UM patients treated with immunotherapy was not significantly different from that of patients treated with chemotherapy (HR=0.98, 95% CI: 0.66–1.44) p=0.92, with an unadjusted median OS of 13.38 months [IQR=6.03-29.57] and 11.02 months [IQR=6.13-23.93], respectively. Conclusion. Immunotherapy significantly improves OS for MM. The prognosis of metastatic UM remains poor. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Oncology is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder